Posted by Michael Wonder on 18 Jul 2024
Sellas announces US FDA rare paediatric disease designation granted to SLS009 for the treatment of paediatric acute myeloid leukaemia
16 July 2024 - Opened enrollment for paediatric AML patients in on-going Phase 2 clinical trial.
Sellas Life Sciences today announced that the US FDA has granted rare paediatric disease designation to SLS009, a highly selective CDK9 inhibitor, for the treatment of paediatric acute myeloid leukaemia.
